Therapeutic Science and Strategy

22:55

Playing Nicely with Friends: How to Make Choices on...

Therapeutic Science and Strategy ·

2026/07/09

Pharma portfolios can create powerful opportunities, but without clear positioning, brands can end up competing with each other. In this episode, Lumanity's Jakub Kaczor, VP, Strategy Consulting, and Peter Smith, SVP, Strategy Consulting, discuss the complexities of portfolio positioning in the pharmaceutical industry. The guests explain that while a focused R&D strategy drives commercial growth and sustained innovation, it also creates a paradox where a company's own assets can end up competing

en

24:17

Policy Convergence and the Future of Pharma Value...

Therapeutic Science and Strategy ·

2026/06/16

In the volatility caused by policy convergence, the future belongs to organizations that can intelligently navigate inflection points that precede launch In this episode, Steve Mather, Global Practice Lead of Strategy and Insight at Lumanity discusses how policy shifts are converging to compress pharma revenue opportunity and force decisive commercial choices much earlier in development. He highlights how IRA time horizons, Europe's Joint Clinical Assessment, and MFN cross-border pricing dynamics

en

24:17

Building a Scalable Pharma Launch Engine that Drives...

Therapeutic Science and Strategy ·

2026/06/02

Most pharma launch frameworks don't fail because they lack structure; they fail because they become rigid checklists that kill strategic thinking. In this episode, Lumanity's Launch Excellence Project Lead, Jeff Hart, and Launch Excellence Principal, Kirsty Tait, talk about how pharmaceutical companies can scale launch excellence as pipelines grow and complexity increases. Kirsty and Jeff explain that rigid, one-size-fits-all frameworks lead to inefficiency, slow decisions, and misalignment across

en

25:17

From Chaos to Confidence: Mastering Pharma Launch as...

Therapeutic Science and Strategy ·

2026/05/19

Launching a pharma product is a high-stakes, pressure-filled marathon where poor planning shows up too late to fix. In this episode, Andrew Mooney and Laurence Cooper break down how early planning, focused strategy, and disciplined execution help smaller pharma teams succeed in high-pressure launches. If you're preparing for a first-time or early-stage pharma launch, this conversation breaks down exactly how to stay focused, avoid costly surprises, and execute with confidence!

en

18:39

The Positioning Compass: Guiding Pharma Brands from...

Therapeutic Science and Strategy ·

2026/05/06

Great pharma brands don't wait for the market to define them; they define themselves through clear, early, and evolving positioning. In this episode, Vice President Natalie Thovmasian and Managing Consultant Liv Yates, highlight that brand positioning is a strategic driver across the entire pharma lifecycle, not just a launch activity. They stress the importance of shaping positioning early, before clinical data, by defining a bold vision through a target product profile and grounding it in customer

en

37:12

The Health Gap: Confronting Barriers to Care in...

Therapeutic Science and Strategy ·

2026/03/19

In the third episode of our Patient Progress podcast series, we look at the hidden and not-so-hidden barriers that keep marginalized communities from getting the mental and physical healthcare they need. Advocates Sarah Renee and Daniel Newman join host Jenny Payne for a candid conversation about how cost, stigma, and institutional biasintersect to make care harder to reach—and how these obstacles affect both mental and physical health. Through their lived experiences, Sarah Renee and Daniel reveal

en

47:10

Patient Progress: Barriers to Care: How Access and...

Therapeutic Science and Strategy ·

2026/01/29

In Episode 2 of our Patient Progress podcast series, we hear directly from those living with mental illness about the obstacles they face: the cost of care, insurance hurdles, and the lack of consistent support services that can mean the difference between getting well and going without. Advocates Kody Green and Gabe Howard share candid stories that reveal why access and affordability aren't just policy issues – they're human ones, affecting people across the spectrum of health needs. Listen now and

en

27:14

Beyond the Data: Building Real Competitive Readiness

Therapeutic Science and Strategy ·

2025/12/22

During this conversation with Outcomes Rocket, Sandy Richardson and Zoe Brown, Principals at Lumanity, talk about why organizations struggle to turn massive amounts of competitive intelligence into actionable strategy. In part 2, Sandy and Zoe discuss how companies can move beyond information overload to build true competitive readiness through focus, collaboration, and action. They explain why real insight comes from asking the right questions, filtering out noise, and fostering ongoing, structured

en

22:00

Fixing Care Breakdowns Through Data, Behavioral...

Therapeutic Science and Strategy ·

2025/12/11

During this conversation, Sandy Richardson and Zoe Brown, Principals at Lumanity, talk about why organizations struggle to turn massive amounts of competitive intelligence into actionable strategy. In part 1, Sandy and Zoe explain how today's "sea of sameness" makes true differentiation harder than ever, and how teams often remain "data rich but time poor," missing early signals of competitive threats. They also break down how overreliance on clinical data, short planning cycles, and internal focus

en

35:03

Patient Progress: Mental Health in Caregivers

Therapeutic Science and Strategy ·

2025/10/07

Caregivers are often the unsung heroes of healthcare: key decision‑makers, advocates, researchers, and emotional anchors. Yet, support for their own mental health is frequently absent. In this episode, Lumanity's Jenny Payne sits down with Ashlee Cramer and Ceinwen Giles to break misconceptions (“Caregivers are saints and happy to do it”) and discuss the real impact — from anxiety, depression, and burnout to post‑traumatic growth (PTG). We explore how caregiving can mean sacrificing careers, social

en

09:38

Key Oncology Takeaways from ESMO 2024

Therapeutic Science and Strategy ·

2024/10/16

During this episode, Lumanity experts Rob Rawlinson and Kate Goacher discuss insights and takeaways from their recent attendance at the 2024 European Society for Medical Oncology (ESMO) conference. Their conversation covers a variety of topics, including: The importance of the patient and including the patient voice in drug development The way that Artificial Intelligence (AI) could impact and innovate cancer care Insights on a selection of early-phase extensive-stage small-cell lung cancer

en

28:31

Embracing the Pediatric Voice from Childhood Through...

Therapeutic Science and Strategy ·

2024/09/30

In this episode, we talk about the concerns, misconceptions, and the value of engaging directly with and including the pediatric voice in market research

en

16:44

Communications Testing Research: Unlock the Power of...

Therapeutic Science and Strategy ·

2024/05/15

In our latest Lumanity bitesize podcast, we explore how to avoid the common challenges and pitfalls encountered in communication testing research, and share best practices in applying a behavioural science lens to bring about stakeholder behaviour change. Our discussion includes: The importance of evaluating concepts using the right criteria Generating maximum impact using clear and simple ads that cut through the noise Being vigilant that the insights being used are robust and precise - and

en

29:53

Supporting Rare Disease Communities

Therapeutic Science and Strategy ·

2024/02/28

In this special podcast episode in honor of Rare Disease Day 2024, Angela Wheeler, President of Insight at Lumanity and Dr. Karin Hoelzer, Director of Policy and Regulatory Affairs at the National Organization for Rare Disorders (NORD), discuss opportunities for pharmaceutical companies to work with and support rare disease communities. Learn how NORD is strengthening collaboration between pharmaceutical companies and rare disease communities, and examples of the positive impact that can be made

en

26:12

Making Social Media Listening Insights Count: Live or...

Therapeutic Science and Strategy ·

2024/01/24

In this podcast episode, we explore the rich potential of social media listening (SML) insights, and how, when interpreted and acted on, they can have a significant impact on commercial decision-making. Hear from Lumanity experts as they bring SML to life using several real world examples. Topics include: How the agility, flexibility and insights from SML research are being harnessed to help improve commercial decisions How SML best complements traditional research and data The value of SML in

en

18:06

Ensuring the Responsible and Meaningful Use of...

Therapeutic Science and Strategy ·

2023/12/07

In this podcast episode, we explore the fascinating world of artificial intelligence and its impact on the healthcare industry, as well as the ever evolving realm of research and its potentially transformative power on decision making. Hear from Lumanity experts Damian Eade, Head of Digital Insights and Analytics, Gemma Spickernell, Director of Behavioral Science, and Andrew Wood, Head of Behavioral Science as they discuss how to navigate the balance between the benefits of AI while ensuring

en

30:27

The Importance of RWE Strategy Planning

Therapeutic Science and Strategy ·

2023/11/02

There are incredible synergies with joint HEOR and Real World Evidence (RWE) projects, but there are also unique challenges. In this podcast episode, The Importance of RWE Strategy Planning, Ann-Marie Chapman, Nikita Jeswani, Meena Venkatachalam, and Alex Thorel discuss the use cases and planning for RWE, identifying appropriate RWE, and RWE trends. Listen to this podcast to learn: · Key considerations, steps, and recommendations in identifying appropriate data sources · Where

en

28:15

Launch Excellence Alchemy: Managing Strategic Risk

Therapeutic Science and Strategy ·

2023/06/05

Strategic risk is often overlooked within the pharmaceutical industry. There’s a perception that someone else is picking up the risk ball. Or there is more of a focus on internal risks, with little thought to the larger external factors that can have a significant impact on your launch. We see common risks arise from competitor launches, multi-indication launches, and supply chain issues. Unmitigated risks can lead to costly delays. So, what can you do to identify the risks for your asset launch

en

28:40

Launch Excellence Alchemy: Mindset, Leadership, and...

Therapeutic Science and Strategy ·

2023/05/09

We know that effective collaboration across cross-functional and global/local launch teams is one of the critical elements to launch success – but teams often struggle to develop the right behaviors that foster a truly collaborative culture. Leadership styles too play a vital role, with research directing us away from ‘leading from the front’, towards a model that champions interdependent leadership and shared accountability. In the second episode of our series on launch excellence, we explore how:

en

19:46

Possible Implications of the Inflation Reduction Act...

Therapeutic Science and Strategy ·

2023/05/02

In this episode, Dr. Nancy McGee and Rob Rawlinson discuss potential implications of the Inflation Reduction Act (IRA) legislation that was passed in the U.S. in 2022. This episode covers: An overview of the IRA in relation to healthcare The potential impacts for oncology patients, manufacturers, and oncologists The impact of the legislation outside of the U.S. Speakers: Nancy McGee, JD, MPH, DrPH, Senior Vice President, Health Policy & Public Payers, Lumanity Rob Rawlinson, Director, Oncology

en

All Episodes

Similar Podcasts

NÖÖRDS - Der Podcast

NÖÖRDS

生命科学の冒険者

あき、とみー

People Who Read People: A Behavior and Psychology Podcast

Zachary Elwood

MEER Media

MEER (Mirrors for Earth"s Energy...

Vintage Sci-Fi Story Anthology

Various